Effimune, launch of an hepatocellular carcinoma study

25 May 2016

OSE Pharma and Effimune announce the launch of a non-interventional study in hepatocellular carcinoma under a private-public collaborative program.

Paris, Nantes – May 19, 2016, 17:45pm – OSE Pharma SA (ISIN: FR0012127173; Ticker: OSE), an immuno-oncology company with a specific immunotherapy activating T lymphocytes, currently in a registration Phase 3 study, and Effimune, a biotech company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immune-oncology, today announce the launch of a non-interventional study in patients with hepatocellular carcinoma (primary liver cancer). This study is a private-public research program supported by the French National Cancer Institute (INCa, Institut National du Cancer) and the Direction Générale de l’Offre de Soins (DGOS, the French access to healthcare services).


Effimune Press Release